Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Winston Salem, North Carolina 27157


Purpose:

The purpose of this research study is to evaluate the effects of the non-medicated part of Xenaderm® Ointment on the rate of healing when people use it to treat superficial (skin-deep) wounds.


Criteria:

Inclusion Criteria: - Provide written informed consent, which will consist of reading, signing, and dating the informed consent document after the Investigator, sub-Investigator or other designated study staff member has explained the study procedures, risks and contact information. - Are male or female, ≥ 18 years of age, of any race. - Are willing to attend all required study visits, and to comply with study procedures. - Meet none of the exclusion criteria (any single exclusion criterion which is met by a potential subject will disqualify that subject from participation in this study). Exclusion Criteria: - Have a history of dermatomyositis, systemic sclerosis, scleroderma, Sjögren's syndrome, systemic lupus erythematosis, discoid lupus, Ehler's Danlos disease, icthyosis vulgaris, vasculitis or bleeding disorders (coagulopathies). - Have any dermatologic disease which may be aggravated or provoked by the wounding procedure, such as Lichen Planus, Psoriasis or Vitiligo. - Have Fitzpatrick scale skin type 6 (never sunburns, deeply pigmented). - Are at risk of keloid or hypertrophic scar formation, based on personal history, family history, or brief skin exam (conducted at the screening visit to look for keloids or hypertrophic scars). - Have been treated within the last three months for uncontrolled diabetes mellitus, peripheral vascular disease, vitamin C deficiency, connective tissue disorders, or any other disease process that impedes wound healing. - Are taking concomitant medications at doses which are known to interfere with healing, such as non-steroidal anti-inflammatory drugs, anti-neoplastic drugs, or immunosuppressive drugs. - Are using topical glycolic acid products, alpha-hydroxy acid products, retinoids or chemical peel agents in the treatment areas. - Are using systemic steroids or immunosuppressant agents, or have used these drugs within the past three months.


NCT ID:

NCT00693810


Primary Contact:

Principal Investigator
Steve Feldman, MD, PhD
Wake Forest University


Backup Contact:

N/A


Location Contact:

Winston Salem, North Carolina 27157
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: January 22, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.